Table 3.
Non-Severe Exacerbations, Pulmonary Function and Use of Healthcare Resources/Absenteeism Before and After One-Year Treatment with Omalizumab (n=240)
| Variables | Before Treatment | After Treatment | P-value* |
|---|---|---|---|
| Non-severe exacerbations, median (Q1; Q3) | 5.0 (3.0; 8.5)a | 0.0 (0.0; 2.0)b | |
| Change | -4.0 (−7.0; −2.0) | <0.0001 | |
| Pulmonary function (FEV1%), median (Q1; Q3) | 71.5 (61.0; 84.0) | 84.0 (78.0; 94.0)c | |
| Change | 12.0 (4.0; 23.0) | <0.0001 | |
| Use of Healthcare Resources/Absenteeism Due to Non-Severe Exacerbations, Median (Q1; Q3) | |||
| Unplanned visits to Primary care | 4.0 (2.0; 6.0)d | 0.0 (0.0; 1.0)e | |
| Change | −3.0 (−5.0; −1.0) | <0.0001 | |
| Unplanned visits to specialists | 1.0 (0.0; 3.0)e | 0.0 (0.0; 0.0)f | |
| Change | −1.0 (−2.0; 0.0) | <0.0001 | |
| School or workplace absenteeism, days | 0.0 (0.0; 14.0)g | 0.0 (0.0; 0.0)h | |
| Change | 0.0 (−11.0; 0.0) | <0.0001 | |
Notes: an=224; bn=234; cn=238; dn=209; en=226; fn=233; gn=180; hn=217. *Wilcoxon signed-rank test.